221 related articles for article (PubMed ID: 20059527)
1. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
Takamatsu Y; Suzumiya J; Utsunomiya A; Maeda K; Matsuoka H; Suzushima H; Tsukada J; Shibata K; Tamura K;
Eur J Haematol; 2010 May; 84(5):391-7. PubMed ID: 20059527
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.
Tsurumi H; Hara T; Goto N; Kanemura N; Kasahara S; Sawada M; Yasuda I; Yamada T; Shimizu M; Takami T; Moriwaki H
Hematol Oncol; 2007 Sep; 25(3):107-14. PubMed ID: 17457949
[TBL] [Abstract][Full Text] [Related]
3. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
5. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
7. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
8. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
9. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
Tomita N; Kodama F; Tsuyama N; Sakata S; Takeuchi K; Ishibashi D; Koyama S; Ishii Y; Yamamoto W; Takasaki H; Hagihara M; Kuwabara H; Tanaka M; Hashimoto C; Yamazaki E; Koharazawa H; Fujimaki K; Sakai R; Fujisawa S; Ishigatsubo Y
Hematol Oncol; 2015 Mar; 33(1):9-14. PubMed ID: 24519501
[TBL] [Abstract][Full Text] [Related]
10. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
14. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
17. Effect of pirarubicin for elderly patients with malignant lymphoma.
Aoki S; Tsukada N; Nomoto N; Maruyama S; Takahashi M; Moriyama Y; Shibata A; Aizawa Y
J Exp Clin Cancer Res; 1998 Dec; 17(4):465-70. PubMed ID: 10089069
[TBL] [Abstract][Full Text] [Related]
18. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
19. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
20. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
